Search

Your search keyword '"Yang, J.C.H."' showing total 22 results
Start Over Author "Yang, J.C.H."
22 results on '"Yang, J.C.H."'

1. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Author

Park, K., Vansteenkiste, J., Lee, K.H., Pentheroudakis, G., Zhou, C., Prabhash, K., Seto, T., Voon, P.J., Tan, D.S.W., Yang, J.C.H., Wang, J., Babu, K. Govind, Nakayama, Y., Alip, A., Chua, K.L.M., Cheng, J.C.-H., Senan, S., Ahn, Y.C., Kim, T.-Y., Ahn, H.K., Peters, S., Yoshino, T., and Douillard, J.-Y.

Published
2020
Full Text
View/download PDF

2. P2.08-01 TROPION-Lung08: Datopotamab Deruxtecan Plus Pembrolizumab in Untreated Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC)

Author

Zhou, C., primary, Levy, B.P., additional, Sands, J., additional, Parakh, S., additional, Sugawara, S., additional, Syrigos, K., additional, Ahn, J.S., additional, Zhao, M., additional, Lin, C.-C., additional, Felip, E., additional, Cappuzzo, F., additional, Reck, M., additional, Yang, J.C.H., additional, Joseph, R., additional, Rawat, S., additional, Xie, J., additional, and Okamoto, I., additional

Published
2023
Full Text
View/download PDF

3. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

Author

Passaro, A., primary, Leighl, N., additional, Blackhall, F., additional, Popat, S., additional, Kerr, K., additional, Ahn, M.J., additional, Arcila, M.E., additional, Arrieta, O., additional, Planchard, D., additional, de Marinis, F., additional, Dingemans, A.M., additional, Dziadziuszko, R., additional, Faivre-Finn, C., additional, Feldman, J., additional, Felip, E., additional, Curigliano, G., additional, Herbst, R., additional, Jänne, P.A., additional, John, T., additional, Mitsudomi, T., additional, Mok, T., additional, Normanno, N., additional, Paz-Ares, L., additional, Ramalingam, S., additional, Sequist, L., additional, Vansteenkiste, J., additional, Wistuba, I.I., additional, Wolf, J., additional, Wu, Y.L., additional, Yang, S.R., additional, Yang, J.C.H., additional, Yatabe, Y., additional, Pentheroudakis, G., additional, and Peters, S., additional

Published
2022
Full Text
View/download PDF

4. Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

Author

Gadgeel, S., Shaw, A.T., Barlesi, F., Crino, L., Yang, J.C.H., Dingemans, A.M., Kim, D.W., de Marinis, F., Schulz, M., Liu, S.Y., Gupta, R., Smoljanovic, V., Ou, S.H.I., RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Pulmonologie, and MUMC+: MA Med Staf Spec Longziekten (9)

Subjects
non-small-cell lung cancer, NP28673, NP28761, alectinib, time to response
Abstract

Introduction: Alectinib is a highly selective and potent ALK inhibitor, approved for the treatment of patients with metastatic ALK+ NSCLC based on results from the Phase II global NP28673 (NCT01801111) and North American NP28761 (NCT01871805) studies.Methods: This exploratory analysis of two Phase II studies of alectinib (NP28673/ NP28761) investigated time to systemic response (TTR) and time to central nervous system (CNS) response (TTCR) in patients with previously treated advanced anaplastic lymphoma kinase fusion gene-positive (ALK+) non-small-cell lung cancer. Patients (n=225) received 600 mg oral alectinib twice daily and had scans every 6/8 weeks (NP28673/NP28761).Results: For NP28673 and NP28761, respectively: median follow-up was 21.3 months/17.0 months; most responders (72.6%/82.9%) responded by the first disease assessment; median TTR was 8 weeks (95% confidence interval [CI]: 8.00-8.14)/6 weeks (95% CI: 5.86-6.14); median TTCR in responders with measurable baseline CNS disease was 8 weeks (95% CI: 7.86-10.29)/6 weeks (95% CI: 5.71-not evaluable). Similar results were observed regardless of measurable/non-measurable disease.Discussion: These data suggest that alectinib achieves a rapid response in patients, both systemically and in the CNS.

Published
2019

7. Analyses des risques concurrents de progression systémique ou au niveau du système nerveux central chez des patients avec CBNPC EGFR muté ayant reçu de l’afatinib dans les études LUX-Lung 3, 6 et 7

Author

Wu, Y.L., primary, Yang, J.C.H., additional, Hirsh, V., additional, O’byrne, K., additional, Yamamoto, N., additional, Popat, S., additional, Tamiya, A., additional, Märten, A., additional, Schuler, M., additional, and Girard, N., additional

Published
2019
Full Text
View/download PDF

9. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

Author

Gautschi, O., Milia, J., Filleron, T., Wolf, J., Carbone, D.P., Owen, D., Camidge, R., Narayanan, V., Doebele, R.C., Besse, B. de, Remon-Masip, J., Janne, P.A., Awad, M.M., Peled, N., Byoung, C.C., Karp, D.D., Heuvel, M. van den, Wakelee, H.A., Neal, J.W., Mok, T.S.K., Yang, J.C.H., Ou, S.I., Pall, G., Froesch, P., Zalcman, G., Gandara, D.R., Riess, J.W., Velcheti, V., Zeidler, K., Diebold, J., Fruh, M., Michels, S., Monnet, I., Popat, S., Rosell, R., Karachaliou, N., Rothschild, S.I., Shih, J.Y., Warth, A., Muley, T., Cabillic, F., Mazieres, J., Drilon, A., Gautschi, O., Milia, J., Filleron, T., Wolf, J., Carbone, D.P., Owen, D., Camidge, R., Narayanan, V., Doebele, R.C., Besse, B. de, Remon-Masip, J., Janne, P.A., Awad, M.M., Peled, N., Byoung, C.C., Karp, D.D., Heuvel, M. van den, Wakelee, H.A., Neal, J.W., Mok, T.S.K., Yang, J.C.H., Ou, S.I., Pall, G., Froesch, P., Zalcman, G., Gandara, D.R., Riess, J.W., Velcheti, V., Zeidler, K., Diebold, J., Fruh, M., Michels, S., Monnet, I., Popat, S., Rosell, R., Karachaliou, N., Rothschild, S.I., Shih, J.Y., Warth, A., Muley, T., Cabillic, F., Mazieres, J., and Drilon, A.

Abstract

Item does not contain fulltext, Purpose In addition to prospective trials for non-small-cell lung cancers (NSCLCs) that are driven by less common genomic alterations, registries provide complementary information on patient response to targeted therapies. Here, we present the results of an international registry of patients with RET-rearranged NSCLCs, providing the largest data set, to our knowledge, on outcomes of RET-directed therapy thus far. Methods A global, multicenter network of thoracic oncologists identified patients with pathologically confirmed NSCLC that harbored a RET rearrangement. Molecular profiling was performed locally by reverse transcriptase polymerase chain reaction, fluorescence in situ hybridization, or next-generation sequencing. Anonymized data-clinical, pathologic, and molecular features-were collected centrally and analyzed by an independent statistician. Best response to RET tyrosine kinase inhibition administered outside of a clinical trial was determined by RECIST v1.1. Results By April 2016, 165 patients with RET-rearranged NSCLC from 29 centers across Europe, Asia, and the United States were accrued. Median age was 61 years (range, 29 to 89 years). The majority of patients were never smokers (63%) with lung adenocarcinomas (98%) and advanced disease (91%). The most frequent rearrangement was KIF5B-RET (72%). Of those patients, 53 received one or more RET tyrosine kinase inhibitors in sequence: cabozantinib (21 patients), vandetanib (11 patients), sunitinib (10 patients), sorafenib (two patients), alectinib (two patients), lenvatinib (two patients), nintedanib (two patients), ponatinib (two patients), and regorafenib (one patient). The rate of any complete or partial response to cabozantinib, vandetanib, and sunitinib was 37%, 18%, and 22%, respectively. Further responses were observed with lenvantinib and nintedanib. Median progression-free survival was 2.3 months (95% CI, 1.6 to 5.0 months), and median overall survival was 6.8 months (95% CI, 3.9 to 14.3 months). Co

Published
2017

10. First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials

Author

Schuler, M., primary, Paz-Ares, L., additional, Sequist, L.V., additional, Tan, E.H., additional, Mok, T., additional, Hirsh, V., additional, O’Byrne, K., additional, Zhang, L., additional, Yamamoto, N., additional, Boyer, M., additional, Shah, R., additional, Bennouna, J., additional, Dickgreber, N.J., additional, De Grève, J., additional, Love, J., additional, Märten, A., additional, Fan, J., additional, Ehrnrooth, E., additional, Park, K., additional, and Yang, J.C.H., additional

Published
2017
Full Text
View/download PDF

11. Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)

Author

Hirsh, V., primary, Park, K., additional, Tan, E.H., additional, Zhang, L., additional, O’Byrne, K., additional, Boyer, M., additional, Yang, J.C.H., additional, Mok, T., additional, Lee, K.H., additional, Lu, S., additional, Shi, Y., additional, Kim, S.W., additional, Laskin, J., additional, Kim, D.W., additional, Laurie, S.A., additional, Kölbeck, K., additional, Fan, J., additional, Dodd, N., additional, Märten, A., additional, and Paz-Ares, L., additional

Published
2017
Full Text
View/download PDF

12. Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors or lymphoma

Author

Lin, C.C., primary, Su, W.C., additional, Chao, Y., additional, Lee, J.H., additional, Hsu, C.H., additional, Cheng, A.L., additional, Chung, W.P., additional, Chen, M.H., additional, Lin, C.L., additional, Ho, H.L., additional, Huang, L.P., additional, Huang, C.T., additional, Hsueh, S.P., additional, and Yang, J.C.H., additional

Published
2016
Full Text
View/download PDF

13. EGFR Mutation Status Is Associated With Better Radiographic Response and Predicts Favorable Outcomes in Non-Small Cell Lung Cancer Patients With Brain Metastases Treated by Stereotactic Radiosurgery

Author

Yang, W.C., primary, Xiao, F.R., additional, Shih, J.Y., additional, Ho, C.C., additional, Chen, Y.F., additional, Tseng, H.M., additional, Chen, K.Y., additional, Liao, W.Y., additional, Yu, C.J., additional, Yang, J.C.H., additional, Kuo, S.H., additional, Cheng, J.C.H., additional, Yang, P.C., additional, and Hsu, F.M., additional

Published
2015
Full Text
View/download PDF

14. 3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies

Author

Goss, G.D., primary, Yang, J.C.H., additional, Ahn, M.J., additional, Tsai, C.M., additional, Bazhenova, L., additional, Sequist, L.V., additional, Ramalingam, S.S., additional, Shepherd, F.A., additional, Ghiorghiu, S., additional, Cantarini, M., additional, Mann, H., additional, Mitsudomi, T., additional, and Jänne, P.A., additional

Published
2015
Full Text
View/download PDF

15. 3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC)

Author

Barlesi, F., primary, Dingemans, A.M.C., additional, Ou, I., additional, Ahn, J.S., additional, Petris, L.D., additional, Kim, D.W., additional, Yang, J.C.H., additional, Hughes, B., additional, Lena, H., additional, Moro-Sibilot, D., additional, Bearz, A., additional, Viteri, S., additional, Mekhail, T., additional, Spira, A., additional, Zeaiter, A., additional, Bordogna, W., additional, Sturm, C., additional, Golding, S., additional, Morcos, P.N., additional, and Govindan, R., additional

Published
2015
Full Text
View/download PDF

17. 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies

Author

Ahn, M.J., primary, Tsai, C.M., additional, Yang, J.C.H., additional, Shepherd, F.A., additional, Satouchi, M., additional, Kim, D.W., additional, Bazhenova, L., additional, Hirashima, T., additional, Rukazenkov, Y., additional, Cantarini, M., additional, Mann, H., additional, Ramalingam, S.S., additional, Mitsudomi, T., additional, Jänne, P.A., additional, and Goss, G.D., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results